Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness and safety of atezolizumab + bevacizumab for unresectable hepatocellular carcinoma in China
ChiCTR2500109767Phase 4Not yet recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Xi'an International Medical Center Hospital. Primary endpoints: Real-world overall survival and TRAE, SAE, and adverse event-related death. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500109767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109767.